INSR and metabolic disease: Therapeutically, our data also show that CDK6 could be better therapeutic target in metabolic diseases than CDK4, a cyclin-dependent kinase that has been implicated in metabolism by phosphorylating PGC-1α43 and insulin receptor substrate 244.